
Raia Drogasil S.A.
RD Saude
Raia Drogasil S.A. (trading as RD Saude) is a Brazilian pharmaceutical retail and healthcare services corporation headquartered in Sao Paulo, State of Sao Paulo, with roots dated to 1905. It is listed on the Novo Mercado governance segment of B3 under ticker RADL3. Control is exercised through a shareholders agreement among the founding Pipponzi, Galvao, and Pires Oliveira Dias families, who together hold approximately 26.6% of total common shares against a free float of roughly 72.8%; the Pipponzi block alone accounts for 11.2%. Scale is large and national: FY2025 revenue of USD 8.05 billion, net income of USD 0.24 billion, total assets of BRL 25.17 billion, and equity of BRL 7.34 billion, delivered by 75,594 employees as of 30 June 2026. The network comprises 3,547 retail pharmacies and 14 distribution centers across all 27 Brazilian federative units, reaching 663 municipalities and more than 50 million active retail and digital customers.
Strengths: Density is the first advantage: 3,547 stores in 663 municipalities give RD coverage no listed rival matches, and 14 distribution centers positioned across all 27 federative units shorten replenishment cycles and support the private-label and dermocosmetic mix. The second is the customer base itself, over 50 million active retail and digital customers, which feeds the loyalty and subscription assets (Stix Fidelidade, Vitat) and lowers acquisition cost per transaction. Third, a portfolio of owned brands, including Needs, Nutrigood, Natumi, Triss, Univers, and Manipulae, captures margin that would otherwise sit with distributors. Fourth, profitability is compounding on a modest base: adjusted net income rose 9.2% year-over-year to BRL 439.1 million in 3Q26, after a 7.4% gain to BRL 432 million in 2Q26 and a near-70% jump to BRL 299.8 million in 1Q26.
Weaknesses: The equity story is now rate-sensitive and volatile: RADL3 shares retreated 24.3% on 11 November 2026 during a broader Brazilian equity correction, and the free float of about 72.8% leaves the stock exposed to institutional flows rather than anchored by a majority holder. Second, net margin is thin for the revenue base, with FY2025 net income of USD 0.24 billion on USD 8.05 billion of revenue, so small shifts in gross margin or the sales, general and administrative line move earnings disproportionately. Third, the store estate is a fixed-cost commitment: 3,547 pharmacies plus 14 distribution centers must be leased, staffed, and stocked, and the 75,594 headcount is largely non-flexible in a soft demand quarter. Fourth, revenue in USD terms has been uneven, moving from USD 7.00 billion in FY2023 to USD 6.29 billion in FY2024 before recovering to USD 8.05 billion in FY2025, which reflects both operating performance and currency translation rather than a clean growth line.
Read MoreShow Less
Raia Drogasil S.A. (trading as RD Saude) is a Brazilian pharmaceutical retail and healthcare services corporation headquartered in Sao Paulo, State of Sao Paulo, with roots dated to 1905. It is listed on the Novo Mercado governance segment of B3 under ticker RADL3. Control is exercised through a shareholders agreement among the founding Pipponzi, Galvao, and Pires Oliveira Dias families, who together hold approximately 26.6% of total common shares against a free float of roughly 72.8%; the Pipponzi block alone accounts for 11.2%. Scale is large and national: FY2025 revenue of USD 8.05 billion, net income of USD 0.24 billion, total assets of BRL 25.17 billion, and equity of BRL 7.34 billion, delivered by 75,594 employees as of 30 June 2026. The network comprises 3,547 retail pharmacies and 14 distribution centers across all 27 Brazilian federative units, reaching 663 municipalities and more than 50 million active retail and digital customers.
Strengths: Density is the first advantage: 3,547 stores in 663 municipalities give RD coverage no listed rival matches, and 14 distribution centers positioned across all 27 federative units shorten replenishment cycles and support the private-label and dermocosmetic mix. The second is the customer base itself, over 50 million active retail and digital customers, which feeds the loyalty and subscription assets (Stix Fidelidade, Vitat) and lowers acquisition cost per transaction. Third, a portfolio of owned brands, including Needs, Nutrigood, Natumi, Triss, Univers, and Manipulae, captures margin that would otherwise sit with distributors. Fourth, profitability is compounding on a modest base: adjusted net income rose 9.2% year-over-year to BRL 439.1 million in 3Q26, after a 7.4% gain to BRL 432 million in 2Q26 and a near-70% jump to BRL 299.8 million in 1Q26.
Weaknesses: The equity story is now rate-sensitive and volatile: RADL3 shares retreated 24.3% on 11 November 2026 during a broader Brazilian equity correction, and the free float of about 72.8% leaves the stock exposed to institutional flows rather than anchored by a majority holder. Second, net margin is thin for the revenue base, with FY2025 net income of USD 0.24 billion on USD 8.05 billion of revenue, so small shifts in gross margin or the sales, general and administrative line move earnings disproportionately. Third, the store estate is a fixed-cost commitment: 3,547 pharmacies plus 14 distribution centers must be leased, staffed, and stocked, and the 75,594 headcount is largely non-flexible in a soft demand quarter. Fourth, revenue in USD terms has been uneven, moving from USD 7.00 billion in FY2023 to USD 6.29 billion in FY2024 before recovering to USD 8.05 billion in FY2025, which reflects both operating performance and currency translation rather than a clean growth line.
Listed market data
RADL3.SA · B3 · weeklyHistory →- Market cap
- $4.4 B
- Share price
- BRL 13.98
- 1Y change
- -35.7%
- Recent change
- -2.2%
- Since first close
- ×2,397
- Revenue (TTM)
- $8.1 B
11-13 → 11-16
from 2000-01
Financial history
Full market history- 2026-11BRL 13.98$4.4 B-8.1%
- 2026-10BRL 15.22$4.8 B-17.1%
- 2026-09BRL 18.37$5.8 B-6.3%
- 2026-08BRL 19.60$6.2 B+6.1%
- 2026-07BRL 18.48$5.9 B+9.9%
- 2026-06BRL 16.81$5.3 B-10.1%
- 2026-05BRL 18.69$5.9 B-14.8%
- 2026-04BRL 21.94$7 B-6.8%
- 2026-03BRL 23.53$7.5 B-6.2%
- 2026-02BRL 25.08$8 B+2.4%
- 2026-01BRL 24.50$7.8 B+4.5%
- 2025-12BRL 23.45$7.4 B—
Ownership & Control
Latest available filings- Controlling entity
- Founding families (Pipponzi, Galvão, Pires Oliveira Dias) — ~26.6%
- Company type
- Company
- Insiders
- 25.27%
- Institutions
- 53.51%(347 holders)
- Free float
- 74.62%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
• 3,547 retail pharmacies in operation at year-end 2025, the largest chain footprint in Brazil and Latin America
• Presence in 663 municipalities across all 26 states and the Federal District
• Dispenses branded prescription drugs, generics, and over-the-counter medicines under two separately positioned banners
Private label and owned brands – margin-capturing product portfolio
• Needs, Nutrigood, Natumi, Triss, and Univers cover personal care, nutrition, and daily-use health categories
• Owned brands shift gross margin away from third-party distributors and into the company's own P&L
• Product development is tied to the store network's assortment and shelf space rather than to separate distribution
Distribution and logistics – national replenishment infrastructure
• 14 strategically located distribution centers serving all 27 Brazilian federative units
• Density supports frequent replenishment of 3,547 stores and underpins private-label availability
• Logistics is the main operating lever behind in-store availability and working capital turns
Digital and loyalty – omnichannel customer platform
• More than 50 million active retail and digital customers across the group
• Stix Fidelidade loyalty program acquired to consolidate customer data and repeat purchase
• Vitat adds a digital health and wellness property that sits alongside the retail transaction
Clinical and extended health services – services beyond dispensing
• Clinical pharmacy services offered through the store network
• Manipulae extends the group into manipulation pharmacy and compounded preparations
• Caretech and related assets position the company as a healthcare ecosystem rather than a pure retailer
Capital markets and governance – listed Brazilian corporation
• Common shares trade on B3 under RADL3 within the Novo Mercado segment
• Founding families hold approximately 26.6% under a shareholders agreement, with a free float near 72.8%
• FY2025 revenue of USD 8.05 billion and total assets of BRL 25.17 billion
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $8.1 B | $240 M |
| 2024 | $6.3 B | $200 M |
| 2023 | $7 B | $220 M |
| 2022 | $5.5 B | $190 M |
| 2021 | $4.3 B | $140 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Founded
Employees
Market cap
Factories
Presence
Listing
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $674 B
- Allergan Aesthetics· $533 B
- AbbVie Inc.· $510 B
- F. Hoffmann-La Roche AG· $381 B
- Merck & Co., Inc.· $366 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website B3 : RADL3
